ResearcherUniversity of MiamiActive in the last 2 years
Tulasigeri M. Totiger
Matched on ORCID iD 0000-0002-4262-4458; OpenAlex author ID A5005940775. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 3
- CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis. Co-author DOI 10.1016/j.jcmgh.2025.101606↗
- Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-18-0464↗
- Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-18-0579↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Austin R. Dosch · 3 shared papers, 2018–2025 · strength 0.35
- Paper CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Al… DOI 10.1016/j.jcmgh.2025.101606↗
- Paper Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-18-0464↗
- Paper Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-0579↗
- Supriya Srinivasan · 3 shared papers, 2018–2025 · strength 0.35
- Paper CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Al… DOI 10.1016/j.jcmgh.2025.101606↗
- Paper Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-18-0464↗
- Paper Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-0579↗
- Nipun B. Merchant · 3 shared papers, 2018–2025 · strength 0.35
- Paper CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Al… DOI 10.1016/j.jcmgh.2025.101606↗
- Paper Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-18-0464↗
- Paper Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-0579↗
- Nagaraj S. Nagathihalli · 3 shared papers, 2018–2025 · strength 0.35
- Paper CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Al… DOI 10.1016/j.jcmgh.2025.101606↗
- Paper Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-18-0464↗
- Paper Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-0579↗
- Michael Nathan VanSaun · 3 shared papers, 2018–2025 · strength 0.35
- Paper CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Al… DOI 10.1016/j.jcmgh.2025.101606↗
- Paper Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-18-0464↗
- Paper Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-0579↗
- Anna Bianchi · 1 shared paper, 2025 · strength 0.20
- Iago De Castro Silva · 1 shared paper, 2025 · strength 0.20
- Jashodeep Datta · 1 shared paper, 2025 · strength 0.20
- Samara P. Singh · 1 shared paper, 2025 · strength 0.20
- Haleh Amirian · 1 shared paper, 2025 · strength 0.20
- Siddharth Mehra · 1 shared paper, 2025 · strength 0.20
- Jason A. Castellanos · 2 shared papers, 2018–2019 · strength 0.15
- Xi Chen · 1 shared paper, 2019 · strength 0.08
- Kumaraswamy Malleshappa Honnenahally · 1 shared paper, 2018 · strength 0.07
- Chanjuan Shi · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.